Outcomes of COVID-19 3-Dose Vaccination in Immunocompromised Patients With Hematologic Cancers

This cohort study assesses neutralizing antibody concentrations following a third mRNA-1273 vaccination in immunocompromised patients with hematologic cancers to levels obtained in healthy individuals after the standard 2-dose vaccination schedule.

Read the full article here

Related Articles